title: Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
abstract: OBJECTIVE
  This study compares outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) in patients undergoing saphenous vein graft (SVG) intervention.
  
  
  BACKGROUND
  The safety and efficacy of DES in patients undergoing SVG intervention is controversial.
  
  
  METHODS
  The STENT (Strategic Transcatheter Evaluation of New Therapies) registry is a multicenter U.S. registry evaluating outcomes with DES. Our study population includes patients undergoing PCI of SVG lesions with DES (n = 785) or BMS (n = 343) who completed 9-month or 2-year follow-up. Outcomes were adjusted with propensity analyses.
  
  
  RESULTS
  The DES patients had fewer emergent procedures but had smaller vessels and longer lesions. The DES patients had less death or myocardial infarction at 9 months (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.33 to 0.83, p = 0.006) and less death at 2 years (HR: 0.60, 95% CI: 0.36 to 0.98, p = 0.041). Target vessel revascularization (TVR) was less with DES at 9 months (7.2% vs. 10.0%, HR: 0.36, 95% CI: 0.22 to 0.61, p < 0.001) but was no different by 2 years (18.3% vs. 16.9%, p = 0.86), although adjusted TVR rates were lower (HR: 0.60, 95% CI: 0.40 to 0.90, p = 0.014). The DES reduced TVR at 9 months in SVG lesions with diameter <3.5 mm (8.0% vs. 17.2%, p = 0.013) but not >or=3.5 mm (6.0% vs. 6.6%, p = 0.74).
  
  
  CONCLUSIONS
  Treatment of SVG lesions with DES vs. BMS is effective in reducing TVR at 9 months, although most of this advantage is lost at 2 years. The DES seem safe with less death or myocardial infarction, although selection bias might have affected these results. Our data suggest that DES might have short-term advantages over BMS in SVG lesions with diameter <3.5 mm.
authors.affiliation: The LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina 27408, USA. bbrodie@triad.rr.com
authors.forename: Bruce R
authors.initials: BR
authors.lastname: Brodie
authors.forename: Hadley
authors.initials: H
authors.lastname: Wilson
authors.forename: Thomas
authors.initials: T
authors.lastname: Stuckey
authors.forename: Marcy
authors.initials: M
authors.lastname: Nussbaum
authors.forename: Sherry
authors.initials: S
authors.lastname: Laurent
authors.forename: Barbara
authors.initials: B
authors.lastname: Bradshaw
authors.forename: Angela
authors.initials: A
authors.lastname: Humphrey
authors.forename: Chris
authors.initials: C
authors.lastname: Metzger
authors.forename: James
authors.initials: J
authors.lastname: Hermiller
authors.forename: Fred
authors.initials: F
authors.lastname: Krainin
authors.forename: Stanley
authors.initials: S
authors.lastname: Juk
authors.forename: Barry
authors.initials: B
authors.lastname: Cheek
authors.forename: Peter
authors.initials: P
authors.lastname: Duffy
authors.forename: Charles A
authors.initials: CA
authors.lastname: Simonton
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D001026:Coronary Artery Bypass / Q000009:adverse effects* / Q000401:mortality; D023903:Coronary Restenosis / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008670:Metals; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D057216:Propensity Score; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011474:Prosthesis Design; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D012501:Saphenous Vein / Q000637:transplantation*; D015607:Stents; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D008670:Metals